Fort Sheridan Advisors LLC Sells 185 Shares of Amgen Inc. $AMGN

Fort Sheridan Advisors LLC cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.7% in the second quarter, Holdings Channel reports. The institutional investor owned 6,762 shares of the medical research company’s stock after selling 185 shares during the period. Fort Sheridan Advisors LLC’s holdings in Amgen were worth $1,888,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Pinkerton Wealth LLC lifted its position in shares of Amgen by 4.1% in the second quarter. Pinkerton Wealth LLC now owns 16,126 shares of the medical research company’s stock worth $4,502,000 after purchasing an additional 631 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new stake in Amgen during the 2nd quarter worth about $59,836,000. Van Hulzen Asset Management LLC lifted its position in Amgen by 1.2% during the 2nd quarter. Van Hulzen Asset Management LLC now owns 11,625 shares of the medical research company’s stock worth $3,246,000 after buying an additional 142 shares in the last quarter. Distillate Capital Partners LLC acquired a new position in shares of Amgen during the 2nd quarter worth about $25,454,000. Finally, Boston Family Office LLC grew its holdings in shares of Amgen by 13.1% in the 2nd quarter. Boston Family Office LLC now owns 9,112 shares of the medical research company’s stock valued at $2,544,000 after acquiring an additional 1,056 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $337.49 on Tuesday. The company has a market cap of $181.73 billion, a P/E ratio of 27.60, a P/E/G ratio of 2.61 and a beta of 0.45. The firm’s fifty day moving average price is $308.54 and its two-hundred day moving average price is $295.60. Amgen Inc. has a one year low of $253.30 and a one year high of $345.84. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, topping the consensus estimate of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter in the previous year, the firm posted $5.58 EPS. Amgen’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Stockholders of record on Friday, November 21st will be given a $2.38 dividend. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a dividend yield of 2.8%. Amgen’s dividend payout ratio is presently 73.57%.

Insider Transactions at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. This trade represents a 30.29% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This trade represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 10,908 shares of company stock worth $3,674,966. Company insiders own 0.76% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AMGN shares. Guggenheim upped their target price on Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Truist Financial assumed coverage on Amgen in a report on Monday, November 24th. They issued a “hold” rating and a $318.00 price objective for the company. Morgan Stanley lowered their target price on shares of Amgen from $333.00 to $329.00 and set an “equal weight” rating on the stock in a report on Wednesday, November 5th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Amgen from $280.00 to $285.00 and gave the stock a “hold” rating in a research report on Tuesday, November 11th. Finally, Wall Street Zen raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $333.74.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.